Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

DHSC publishes final list of February price concessions

The Department of Health and Social Care (DHSC) today announced the final list of price concessions for February.

The latest list of prices, revealed by PSNC, follows the first announcement on February 19 and the second one on February 21.


The latest list (below) covers 27 drugs.

DrugPack sizePrice Concession
Amiloride 5mg tablets28£25.40
Clarithromycin 125mg/5ml oral suspension70ml£4.06
Clarithromycin 250mg/5ml oral suspension70ml£5.56
Clonidine 25microgram tablets112£14.44
Cyanocobalamin 50microgram tablets50£9.17
Diclofenac sodium 100mg modified-release tablets28£11.33
Esomeprazole 20mg gastro-resistant capsules28£2.73
Fluoxetine 60mg capsules30£7.49
Imipramine 25mg tablets28£2.97
Irbesartan 300mg tablets28£5.12
Lamotrigine 25mg dispersible tablets sugar free56£6.60
Lamotrigine 100mg dispersible tablets sugar free56£8.99
Mometasone 0.1% cream30g£3.11
Mometasone 50micrograms/dose nasal spray140 dose£5.10
Nefopam 30mg tablets90£10.10
Oxytetracycline 250mg tablets28£3.40
Perindopril erbumine 4mg tablets30£3.49
Perindopril erbumine 8mg tablets30£2.75
Pioglitazone 30mg tablets28£2.08
Pioglitazone 45mg tablets28£2.07
Rivastigmine 1.5mg capsules28£3.11
Sulpiride 200mg tablets30£6.68
Tamoxifen 20mg tablets30£4.99
Tacrolimus 0.1% ointment30g£18.31
Tetracycline 250mg tablets28£4.99
Tizanidine 2mg tablets120£11.80
Valaciclovir 500mg tablets10£19.06

More For You

Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less
NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less